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Francesco Maisano, MDyT ricuspid regurgitation (TR) is a commonﬁnding in patients with left-sided disease,and is associated with poor outcome and pre-
dicts poor survival, heart failure, and reduced func-
tional capacity (1). It is common after mitral valve
treatment in rheumatic or ischemic mitral regurgita-
tion, if left untreated at the time of mitral surgery.
In this subgroup with long-standing TR, managed
medically for a long time, surgical correction can be
more prohibitive due to the presence of variable de-
grees of right ventricular (RV) dysfunction, pulmo-
nary vascular disease, and right heart failure. The
pre-operative condition of the RV and the severity
of secondary renal and hepatic impairment are
predictors of limited survival (2,3). Percutaneous pro-
cedures may be an attractive alternative to surgery
for patients deemed to be high-risk surgical candi-
dates. While the development and clinical use of
percutaneous approaches to the aortic valve and
mitral valve have been widespread over the past
few years, limited data are available about the feasi-
bility and efﬁcacy of percutaneous tricuspid valve
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Ireland) is a percutaneous device designed for TV
remodeling, by means of a transfemoral ﬁxation of a
stainless steel corkscrew into the anteroposterior TV
annulus. The corkscrew is connected through a Dacron
band to a self-expanding nitinol stent. By pulling the
system towards the inferior vena cava (IVC), the
anchoring corkscrew remodels the anteroposterior
annulus, and the tension is maintained by ﬁxation of
the stent in the IVC. The stent is available in different
sizes (27 to 43 mm in diameter, 60 mm in length) to
guarantee oversizing in the hepatic region of the IVC
(Figure 1). The “ﬁrst-in-man” patient was a 72-year-old
woman with severe functional TR associated with
tricuspid annular dilation. She was admitted in New
York Heart Association functional class III after 2 epi-
sodes of decompensated heart failure in the previous
2 months, presenting with edema of the lower ex-
tremities,moderate ascites, jugular venousdistension,
with moderate liver dysfunction due to hepatitis C
(unconjugated bilirubin 2.7 mg/dl) and normal kidney
function (creatinine 1 mg/dl, glomerular ﬁltration rate
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FIGURE 1 The TriCinch TV Repair System
Procedural steps of the TriCinch TV repair system showing reduction of septolateral dimensions (yellow arrows) when cinching and tension is applied on the
annulus in the direction of the inferior vena cava (red arrows). TV ¼ tricuspid valve.
Latib et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 3 , 2 0 1 5
TriCinch TV Repair N O V E M B E R 2 0 1 5 : e 2 1 1 – 4
e212atrial ﬁbrillation and prior aortic valve replacement
withabioprosthesis.TheSTSScore riskofmortalitywas
5.2% (morbidity or mortality 34.7%). Transesophageal
echocardiography revealed grade 4þ TR (with systolic
hepatic vein ﬂow reversal, 9 mm lack of coaptation,
and septolateral dimension of 46 mm at transthoracicFIGURE 2 Baseline Transthoracic Echocardiography of the TV
Baseline tricuspid valve (TV) septolateral dimension and lack of coaptat
echocardiogram.echocardiography [TTE] assessment) (Figure 2), mod-
erate right ventricular dysfunction (tricuspid tissue
Doppler imaging systolic velocity 8 cm/s and systolic
pulmonary artery pressure 42 mm Hg) with a normal
functioning mitral valve, maintained aortic prosthesis
function (mean gradient 6 mm Hg), and normal leftion (A) and severe tricuspid regurgitation (B) at transthoracic
FIGURE 3 CT Scan for Pre-Procedural Planning, TriCinch System Corkscrew, and Stent Implantation
Computed tomography (CT) scan pre-procedural planning (A), TriCinch System corkscrew (B), and stent (C) ﬂuoroscopic implantation. Target
area (asterisk) was identiﬁed at CT scan and ﬂuoroscopic imaging. APC ¼ anteroposterior commissure; ASC ¼ anteroseptal commissure;
AV ¼ aortic valve; MV ¼ mitral valve; TV ¼ tricuspid valve.
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e213ventricular ejection fraction. After multidisciplinary
heart team agreement on the transcatheter TV repair
option with the TriCinch System, the patient was
enrolled in the PREVENT (Percutaneous Treatment of
Tricuspid Valve Regurgitation With the TriCinch
System; NCT02098200) study. Procedural planning,
based on cardiac computed tomography (CT) scan,
predicted the safe anchoring area at the level of the
anterior tricuspid annulus (between the right coro-
nary artery and anterior leaﬂet’s hinge) (Figure 3A)
and the adequate stent size to be used to guarantee
the best vessel oversizing (IVC mean diameter 26 mm,
oversizing 60%). The intervention was performed
under general anesthesia, ﬂuoroscopy, as well as
intracardiac and transesophageal echocardiography
guidance. A 10-F intracardiac echocardiography probe
was inserted via the left femoral vein and a Judkins
right guiding catheter via the left femoral artery to
perform right coronary angiography. A 24-F Gore Dry-
seal sheath was inserted in the right femoral vein for
insertion of the 18-F steerable TriCinch delivery sys-
tem into the right atrium. The tip of the delivery
system was steered toward the target site on the
tricuspid annulus. The corkscrew was inserted into
the annulus. Any interference with the right coronary
artery was ruled out by selective angiography
(Figure 3B). The system was tensioned under echo
guidance until a reduction in septolateral dimension
(intraoperative at transesophageal echocardiographyfrom 41 mm to 38 mm) and in TR grade (from 4þ to
3þ) was observed (Figure 4, Online Video 1) and 5-mm
coaptation length became evident. The cinching of
the tricuspid annulus was maintained by implanta-
tion of a 43-mm self-expanding nitinol stent in the
IVC between the hepatic veins and the right renal
vein (Figure 3C). The procedure was completed un-
eventfully in 56 min, and the patient was discharged 5
days later, with TTE documenting the maintained
remodeling of the TV (TR grade 3þ and septolateral
diameter of 40 mm at TTE assessment) and showing
the device correctly in place with continued tension
on the annulus. At 6-month follow-up, the patient
was in good functional status with improved quality
of life.
The TriCinch is the ﬁrst dedicated TV repair device
to be evaluated in humans in a prospective trial. The
design concept of the TriCinch system was initially
based on mimicking the Kay procedure by cinching at
the anteroposterior commissure and reducing septo-
lateral dimensions. This ﬁrst-in-man case demon-
strates the feasibility and safety of the percutaneous
remodeling of the TV by implanting the TriCinch
device, associated with reduction in annular di-
mensions and TR severity. Although the device only
resulted in a modest reduction in TR, this may be
sufﬁcient for symptomatic improvement in these
patients in whom elimination of TR may be harmful.
This also raises the question as to whether the correct
FIGURE 4 Pre-Procedural and Post-Procedural TEE
Pre-procedural (A and C) and post-procedural (B and D) transesophageal echocardiography (TEE): following TriCinch implantation, tricuspid
regurgitation reduces the tricuspid regurgitation grade from 4þ (A) to 3þ (B), and septolateral annular dimension from 41 mm (C) to 38 mm (D)
(Online Video 1).
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e214measure of efﬁcacy in patients with severe TR is
echocardiographic or symptoms and quality of life.
Longer-term follow-up and more patients are re-
quired to conﬁrm these initial results and will deﬁne
the risk–beneﬁt balance of future TR treatment
strategies.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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APPENDIX For supplemental videos,
please see the online version of this article.
